Hagens Berman Launches Investigation into CVRx Inc. After Significant Stock Decline?#USA#San_Francisco#Securities_Fraud#Hagens_Berman#CVRx_Inc.
Hagens Berman Launches Investigation into CVRx Inc. After Significant Stock Decline?
Hagens Berman is investigating CVRx Inc. due to a massive 59% stock drop linked to potential securities fraud. Investors are urged to take action.
third-news.com
October 1, 2026 at 6:27 PM
Hagens Berman Launches Investigation into CVRx Inc. After Significant Stock Decline?#USA#San_Francisco#Securities_Fraud#Hagens_Berman#CVRx_Inc.
#CVRX CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
https://www.stocktitan.net/news/CVRX/cv-rx-announces-late-breaking-data-and-new-clinical-evidence-on-yw75s9tucwfd.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CVRX/cv-rx-announces-late-breaking-data-and-new-clinical-evidence-on-yw75s9tucwfd.html?utm_source=stocktitan-bluesky&utm_medium=social
CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
CVRx (NASDAQ: CVRX) announced Barostim scientific presentations at the HFSA Annual Scientific Meeting, taking place October 9–12, 2026, in Phoenix. Barostim will feature across eight events, including late-breaking clinical data, posters and podium sessions.Dr. Dmitry Yaranov will present new REBALANCE Registry analyses evaluating Barostim’s safety and benefits in commercial use. Dr. Javed Butler will present a separate session titled “Baroreflex Activation Therapy in HFmrEF: First Real-World Evidence of Reduced Hospitalization Burden.” The BENEFIT-HF trial, initiated earlier this year to evaluate Barostim in an expanded population, will appear in the clinical trial ePoster hub.CVRx will also host two symposia covering Barostim’s integration into heart failure care and practical considerations for developing clinical programs.
www.stocktitan.net
September 29, 2026 at 8:30 PM
#CVRX CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
https://www.stocktitan.net/news/CVRX/cv-rx-announces-late-breaking-data-and-new-clinical-evidence-on-yw75s9tucwfd.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CVRX/cv-rx-announces-late-breaking-data-and-new-clinical-evidence-on-yw75s9tucwfd.html?utm_source=stocktitan-bluesky&utm_medium=social
Jurassic Park (1993) - They remember
YouTube video by Anders Andersson
www.youtube.com
August 11, 2026 at 4:59 PM
STF vai torpedear 1º ataque do Congresso
O Senado aprovou ano passado uma emenda à Constituição que tira poderes do Supremo. Agora, o Tribunal vai mostrar ao Congresso que não tem poderes para isso
www.youtube.com/watch?v=CVrX...
O Senado aprovou ano passado uma emenda à Constituição que tira poderes do Supremo. Agora, o Tribunal vai mostrar ao Congresso que não tem poderes para isso
www.youtube.com/watch?v=CVrX...
STF vai torpedear 1º ataque do Congresso
YouTube video by Blog da Cidadania
www.youtube.com
September 15, 2024 at 1:35 PM
STF vai torpedear 1º ataque do Congresso
O Senado aprovou ano passado uma emenda à Constituição que tira poderes do Supremo. Agora, o Tribunal vai mostrar ao Congresso que não tem poderes para isso
www.youtube.com/watch?v=CVrX...
O Senado aprovou ano passado uma emenda à Constituição que tira poderes do Supremo. Agora, o Tribunal vai mostrar ao Congresso que não tem poderes para isso
www.youtube.com/watch?v=CVrX...
#VRChat API crashed for that long, that people went for #ChilloutVR causing big influx of people, which did caused voice go crunchy, but surprisingly held out. We had peak of 240 people as you see from screenshot (CVRX app).
June 8, 2025 at 8:36 AM
#VRChat API crashed for that long, that people went for #ChilloutVR causing big influx of people, which did caused voice go crunchy, but surprisingly held out. We had peak of 240 people as you see from screenshot (CVRX app).
News; ( NASDAQ: #CVRX ) CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025
#StockMarket #News
#StockMarket #News
November 4, 2024 at 4:45 PM
September 18, 2024 at 7:20 PM
BREAKING NEWS: ( NASDAQ: #CVRX ) CVRx announces new CPT Category I codes for Barostim
#StockMarket #News
#StockMarket #News
October 18, 2024 at 6:35 PM
BREAKING NEWS: ( NASDAQ: #CVRX ) CVRx announces new CPT Category I codes for Barostim
#StockMarket #News
#StockMarket #News
Apropos of nothing: When I started at the NIH I had to return all of my stock options from CVRx. Even though CVRx's neuromod focus was cardiac and I was NINDS, my funding role could create an appearance of conflict of interest. CVRx wasn't public at the time, so I couldn't sell them off.
February 4, 2025 at 2:34 PM
Apropos of nothing: When I started at the NIH I had to return all of my stock options from CVRx. Even though CVRx's neuromod focus was cardiac and I was NINDS, my funding role could create an appearance of conflict of interest. CVRx wasn't public at the time, so I couldn't sell them off.
Pomerantz Law Firm Launches Investigation Into CVRx, Inc. for Potential Investor Misconduct#United_States#New_York#Securities_Fraud#Pomerantz#CVRx
Pomerantz Law Firm Launches Investigation Into CVRx, Inc. for Potential Investor Misconduct
Pomerantz Law Firm is probing claims concerning potential securities fraud at CVRx, Inc. that may affect investors significantly. Stay informed.
third-news.com
February 27, 2026 at 9:07 AM
Pomerantz Law Firm Launches Investigation Into CVRx, Inc. for Potential Investor Misconduct#United_States#New_York#Securities_Fraud#Pomerantz#CVRx
CVRx Guides Q1 Revenue to $14.7M–$14.8M: CVRx projected Q1 revenue of $14.7M–$14.8M on Apr 13, 2026 (midpoint $14.75M), an implied annualized run-rate of ~$59.0M; narrow guidance raises questions about… 👈 Read full analysis #CVRx #RevenueForecast #FinancialNews #InvestmentInsights #HealthcareSector
CVRx Guides Q1 Revenue to $14.7M–$14.8M
CVRx projected Q1 revenue of $14.7M–$14.8M on Apr 13, 2026 (midpoint $14.75M), an implied annualized run-rate of ~$59.0M; narrow guidance raises questions about visibility and sustainability.
dlvr.it
April 13, 2026 at 12:46 PM
CVRx Guides Q1 Revenue to $14.7M–$14.8M: CVRx projected Q1 revenue of $14.7M–$14.8M on Apr 13, 2026 (midpoint $14.75M), an implied annualized run-rate of ~$59.0M; narrow guidance raises questions about… 👈 Read full analysis #CVRx #RevenueForecast #FinancialNews #InvestmentInsights #HealthcareSector
CVRx Barostim Demonstrates Reduction in Health Care Use in Real-World Data
CVRx Barostim Demonstrates Reduction in Health Care Use in Real-World Data - Endovascular Today
February 12, 2025—CVRx, Inc. announced new real-world evidence demonstrating that use of the company’s Barostim implant was associated wit
evtoday.com
February 13, 2025 at 4:26 PM
CVRx Barostim Demonstrates Reduction in Health Care Use in Real-World Data
New CFO at CVRx scaling Barostim. Meanwhile I'm 16 weeks into an echo waitlist wondering who in my waiting room has HF I can't yet prove, mind.
medtechdive.com/news/cvrx-names-john-landry-as-…
medtechdive.com/news/cvrx-names-john-landry-as-…
CVRx names John Landry as CFO
Landry joins in the aftermath of an investor's call for the sale of the heart failure device company.
www.medtechdive.com
September 25, 2026 at 6:40 AM
New CFO at CVRx scaling Barostim. Meanwhile I'm 16 weeks into an echo waitlist wondering who in my waiting room has HF I can't yet prove, mind.
medtechdive.com/news/cvrx-names-john-landry-as-…
medtechdive.com/news/cvrx-names-john-landry-as-…
Cfo swap at cvrx, landry in. The meddevice c-suite carousel spins on, grand
September 25, 2026 at 8:33 AM
Cfo swap at cvrx, landry in. The meddevice c-suite carousel spins on, grand
Industry Symposia sessions start in 15 minutes at #ISHLT2026! We're thankful for today's session supporters Abbott, CareDx, Inc., CVRx, Lung Bioengineering, Paragonix Technologies, and TransMedics, Inc.
April 23, 2026 at 3:30 PM
Industry Symposia sessions start in 15 minutes at #ISHLT2026! We're thankful for today's session supporters Abbott, CareDx, Inc., CVRx, Lung Bioengineering, Paragonix Technologies, and TransMedics, Inc.
$CVRX: Canaccord Reiterates Buy Rating on CVRx Inc (CVRX)
stockoscope.com/stock/cvrx/news#price-targets
stockoscope.com/stock/cvrx/news#price-targets
September 22, 2026 at 2:00 PM
$CVRX: Canaccord Reiterates Buy Rating on CVRx Inc (CVRX)
stockoscope.com/stock/cvrx/news#price-targets
stockoscope.com/stock/cvrx/news#price-targets
New CFO at CVRx. Good for the company. Meanwhile my refractory HF patients in the holler still can't reach a Barostim implanter without a two-hour haul over the mountain. That's the story.
#MedTech #HFpEF #HealthInequality
#MedTech #HFpEF #HealthInequality
September 24, 2026 at 10:23 PM
New CFO at CVRx. Good for the company. Meanwhile my refractory HF patients in the holler still can't reach a Barostim implanter without a two-hour haul over the mountain. That's the story.
#MedTech #HFpEF #HealthInequality
#MedTech #HFpEF #HealthInequality
🚨📣 #insidertrading Nielsen Kirk G. bought $977.3K of $CVRX on 2025-05-12
Insider performance (2020-24):
🟢1d: 0%
🟢3d: 2%
🟢5d: 2%
🔴1m: -1%
🟢3m: 24%
🟢6m: 77%
🟢1y: 95%
total trade: 13
$SPY $QQQ $DIA $VIX
#stock
#stockmarket #NASDAQ #NYSE #OTC
Insider performance (2020-24):
🟢1d: 0%
🟢3d: 2%
🟢5d: 2%
🔴1m: -1%
🟢3m: 24%
🟢6m: 77%
🟢1y: 95%
total trade: 13
$SPY $QQQ $DIA $VIX
#stock
#stockmarket #NASDAQ #NYSE #OTC
May 14, 2025 at 9:30 PM
🚨📣 #insidertrading Nielsen Kirk G. bought $977.3K of $CVRX on 2025-05-12
Insider performance (2020-24):
🟢1d: 0%
🟢3d: 2%
🟢5d: 2%
🔴1m: -1%
🟢3m: 24%
🟢6m: 77%
🟢1y: 95%
total trade: 13
$SPY $QQQ $DIA $VIX
#stock
#stockmarket #NASDAQ #NYSE #OTC
Insider performance (2020-24):
🟢1d: 0%
🟢3d: 2%
🟢5d: 2%
🔴1m: -1%
🟢3m: 24%
🟢6m: 77%
🟢1y: 95%
total trade: 13
$SPY $QQQ $DIA $VIX
#stock
#stockmarket #NASDAQ #NYSE #OTC
CFO change at CVRx, Barostim is going commercial. But here's what keeps me up: we still catch heart failure too late in primary care. No therapeutic out-performs earlier detection.
September 23, 2026 at 11:54 PM
CFO change at CVRx, Barostim is going commercial. But here's what keeps me up: we still catch heart failure too late in primary care. No therapeutic out-performs earlier detection.
#CVRX CVRx Appoints John Landry as Chief Financial Officer
https://www.stocktitan.net/news/CVRX/cv-rx-appoints-john-landry-as-chief-financial-05egihmm6qng.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CVRX/cv-rx-appoints-john-landry-as-chief-financial-05egihmm6qng.html?utm_source=stocktitan-bluesky&utm_medium=social
CVRx Appoints John Landry as Chief Financial Officer
CVRx (CVRX) appointed John Landry as Chief Financial Officer, succeeding Jared Oasheim, with the transition tied to the filing of CVRx’s Form 10‑Q for the quarter ending September 30, 2026.Landry will join CVRx on October 12, 2026 and become CFO after that quarterly filing, while Oasheim remains for a transition period under his previously disclosed agreement. Landry currently serves as CFO of Nyxoah SA and previously spent 12 years at Vapotherm, where he led its IPO and built finance, investor relations and public reporting functions. His earlier roles included finance leadership positions at Salient Surgical Technologies, Bottomline Technologies, Hussey Seating Company and Coopers & Lybrand. Landry holds a B.S. in Accountancy from Bentley College, is a CPA (inactive), and serves on the board of Liberate Medical.
www.stocktitan.net
September 21, 2026 at 8:07 PM
#CVRX CVRx Appoints John Landry as Chief Financial Officer
https://www.stocktitan.net/news/CVRX/cv-rx-appoints-john-landry-as-chief-financial-05egihmm6qng.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CVRX/cv-rx-appoints-john-landry-as-chief-financial-05egihmm6qng.html?utm_source=stocktitan-bluesky&utm_medium=social
🚨 $CVRX
On September 21, 2026, CVRx, Inc. announced that its Board of Directors appointed John Landry as Chief Financial Officer . Mr. Landry succeeds Jared Oasheim who, as previously disclosed on June 8, 2026, gave notice of his intention to resign as CFO after his successor commences in the rol...
On September 21, 2026, CVRx, Inc. announced that its Board of Directors appointed John Landry as Chief Financial Officer . Mr. Landry succeeds Jared Oasheim who, as previously disclosed on June 8, 2026, gave notice of his intention to resign as CFO after his successor commences in the rol...
SEC Filing: CVRX
Click to view the official SEC document.
www.sec.gov
September 21, 2026 at 8:17 PM
🚨 $CVRX
On September 21, 2026, CVRx, Inc. announced that its Board of Directors appointed John Landry as Chief Financial Officer . Mr. Landry succeeds Jared Oasheim who, as previously disclosed on June 8, 2026, gave notice of his intention to resign as CFO after his successor commences in the rol...
On September 21, 2026, CVRx, Inc. announced that its Board of Directors appointed John Landry as Chief Financial Officer . Mr. Landry succeeds Jared Oasheim who, as previously disclosed on June 8, 2026, gave notice of his intention to resign as CFO after his successor commences in the rol...
